Cerecor has launched a c Phase 1b clinical trial (NCT04752371) of the human mAb CERC-007, targeting IL-18, in 12 patients with active adult onset Still’s disease (AOSD). They estimate AOSD affects 3,500 - 7,000 in the US 3,400 - 6,900 pts in Europe https://t.co/DlW1QbXOG0